Approval · Notice of Compliance 14571 · 2013
VOTRIENT: Notice of Compliance 14571
Issued July 19, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14571
- Date
- July 19, 2013
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the indiation for renal cell carcinoma to: Indicated for the first line treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) and for patients who have received prior treatment with cytokines for metastatic disease
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOTRIENT | Not yet assigned | — |
Medicinal ingredients
- PAZOPANIB HYDROCHLORIDE 200 MG per TAB
- PAZOPANIB HYDROCHLORIDE 400 MG per TAB